Education
About Us
Working with TipRanks
Follow Us
Dogwood Therapeutics (DWTX)
NASDAQ:DWTX
Total Valuation
Dogwood Therapeutics has a market cap or net worth of $143.88M. The enterprise value is $96.56M.
Market Cap$143.88M
Enterprise Value$96.56M
Share Statistics
Dogwood Therapeutics has 29,727,865 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding29,727,865
Owned by Insiders83.23%
Owned by Institutions<0.01%
Financial Efficiency
Dogwood Therapeutics’s return on equity (ROE) is -0.19 and return on invested capital (ROIC) is -13.40%.
Return on Equity (ROE)-0.19
Return on Assets (ROA)-0.13
Return on Invested Capital (ROIC)-13.40%
Return on Capital Employed (ROCE)-0.13
Revenue Per Employee0.00
Profits Per Employee-1.03M
Employee Count12
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Dogwood Therapeutics is ―. Dogwood Therapeutics’s PEG ratio is -0.00267.
PE Ratio―
PS Ratio0.00
PB Ratio0.04
Price to Fair Value0.04
Price to FCF-0.29
Price to Operating Cash Flow-0.68
PEG Ratio-0.00267
Income Statement
In the last 12 months, Dogwood Therapeutics had revenue of 0.00 and earned -12.35M in profits. Earnings per share was -12.52.
Revenue0.00
Gross Profit-12.18K
Operating Income-12.23M
Pretax Income-12.35M
Net Income-12.35M
EBITDA-12.25M
Earnings Per Share (EPS)-12.52
Cash Flow
In the last 12 months, operating cash flow was -18.11M and capital expenditures 6.00, giving a free cash flow of -18.11M billion.
Operating Cash Flow-18.11M
Free Cash Flow-18.11M
Free Cash Flow per Share-0.61
Dividends & Yields
Dogwood Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.72
52-Week Price Change35.19%
50-Day Moving Average5.98
200-Day Moving Average5.38
Relative Strength Index (RSI)27.16
Average Volume (3m)1.54M
Important Dates
Dogwood Therapeutics upcoming earnings date is Apr 6, 2026, Before Open (Confirmed).
Last Earnings DateNov 6, 2025
Next Earnings DateApr 6, 2026
Ex-Dividend Date―
Financial Position
Dogwood Therapeutics as a current ratio of 5.21, with Debt / Equity ratio of 0.23%
Current Ratio5.21
Quick Ratio5.21
Debt to Market Cap6.03
Net Debt to EBITDA-0.06
Interest Coverage Ratio-132.63
Taxes
In the past 12 months, Dogwood Therapeutics has paid -503.00 in taxes.
Income Tax-503.00
Effective Tax Rate<0.01
Enterprise Valuation
Dogwood Therapeutics EV to EBITDA ratio is -0.27, with an EV/FCF ratio of -0.38.
EV to Sales0.00
EV to EBITDA-0.27
EV to Free Cash Flow-0.38
EV to Operating Cash Flow-0.38
Balance Sheet
Dogwood Therapeutics has $10.13M in cash and marketable securities with $174.78K in debt, giving a net cash position of $9.95M billion.
Cash & Marketable Securities$10.13M
Total Debt$174.78K
Net Cash$9.95M
Net Cash Per Share$0.33
Tangible Book Value Per Share-$12.88
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Dogwood Therapeutics is $21.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$21.00
Price Target Upside441.24% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast-295.27%